nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-211-3-74-79nogr-2338Research ArticleОБЗОРREVIEWГенетические особенности патогенеза аденокарцином поджелудочной железыGenetic features of pathogenesis in pancreatic adenocarcinomasНабокаМ. В.NabokaM. V.noemail@neicon.ruГараевТ. И.GaraevT. I.noemail@neicon.ruЛяпустинаО. С.LyapustinaO. S.noemail@neicon.ruВьюшковД. М.ViushkovD. M.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияOmsk State Medical UniversityRussian Federation202325072023037479Copyright © Набока М.В., Гараев Т.И., Ляпустина О.С., Вьюшков Д.М., 20232023Набока М.В., Гараев Т.И., Ляпустина О.С., Вьюшков Д.М.Naboka M.V., Garaev T.I., Lyapustina O.S., Viushkov D.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2338

На сегодняшний день проблема онкологических заболеваний под-желудочной железы в высоком проценте летальности. По прогнозам МАИР, к 2030 году рак поджелудочной железы станет второй основной причиной смертности от рака. Поскольку пациенты обычно поступают с прогрессирующим заболеванием и плохо реагируют на химиотерапию широкого спектра действия, общая выживаемость составляет всего 10%. Это подчеркивает острую клиническую необходимость в определении новых терапевтических подходов для пациентов с аденокарциномой поджелудочной железы. Цель: Выявить закономерности генетических изменений в развитии карциномы поджелудочной железы и рассмотреть пути патогенеза данного процесса. Материалы и методы: данные мульти-генетических панелей мемриального онкологического центра имени Слоуна Кеттеринга, статей журнала «Cancers» и статей ресурса PubMed. Результаты: в ходе работы были обнаружены основные и альтернативные пути патогенеза рака поджелудочной железы, установлены гипотезы о схожих путях патогенеза у опухолей других локализаций и о наличии фундаментальных патогенетических звеньях в патогенезе, указывающих на универсальность некоторых генетических изменений в опухолевом росте.

To date, the problem of pancreatic cancer is the high mortality rate. The IARC predicts that pancreatic cancer will become the second leading cause of cancer deaths by 2030. Because patients usually present with advanced disease and respond poorly to broad-spectrum chemotherapy, overall survival is only 10%. This highlights the urgent clinical need to identify new therapeutic approaches for patients with pancreatic adeno-carcinoma. Objective: To identify patterns of genetic changes in the development of pancreatic carcinoma and to consider pathogenesis of this process. Materials and methods: data from multi-genetic panels of Memorial Sloan Kettering Cancer Center, articles of the journal Cancers, and PubMed re-source articles. Results: the work has uncovered major and alternative pathways in the pathogenesis of pancreatic cancer, established hypotheses of similar pathways in tumors of other localizations and the presence of fundamental pathogenetic links in pathogenesis, indicating the universality of certain genetic changes in tumor growth.

поджелудочная железааденокарциномапатогенезопухолевый ростдисплазиямутацииKRASBRCApancreaticadenocarcinomapathogenesistumor growthdysplasiamutationsKRASBRCAReferencesGlobal Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Author: Freddie Bray, Ahmedin Jemal, Isabelle Soerjomataram, et al. Publication: CA: A Cancer Journal for Clinicians Publisher: John Wiley and Sons Date: Feb 4, 2021Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Author: Freddie Bray, Ahmedin Jemal, Isabelle Soerjomataram, et al. Publication: CA: A Cancer Journal for Clinicians Publisher: John Wiley and Sons Date: Feb 4, 2021Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. doi: 10.5114/pg.2018.81072.Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. doi: 10.5114/pg.2018.81072.Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155.Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155.Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, Torrisani J, Cordelier P. Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics. 2011 Mar;12(1):15-24. doi: 10.2174/138920211794520132.Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, Buscail L, Torrisani J, Cordelier P. Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics. 2011 Mar;12(1):15-24. doi: 10.2174/138920211794520132.Distler M, Aust D, Weitz J, Pilarsky C, Grützmann R. Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int. 2014; 2014:474905. doi: 10.1155/2014/474905.Distler M, Aust D, Weitz J, Pilarsky C, Grützmann R. Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int. 2014; 2014:474905. doi: 10.1155/2014/474905.Andea, A., Sarkar, F. & Adsay, V. Clinicopathological Correlates of Pancreatic Intraepithelial Neoplasia: A Comparative Analysis of 82 Cases With and 152 Cases Without Pancreatic Ductal Adenocarcinoma. Mod Pathol. 16, 996-1006 (2003).Andea, A., Sarkar, F. & Adsay, V. Clinicopathological Correlates of Pancreatic Intraepithelial Neoplasia: A Comparative Analysis of 82 Cases With and 152 Cases Without Pancreatic Ductal Adenocarcinoma. Mod Pathol. 16, 996-1006 (2003).Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008; 3:157-88. doi: 10.1146/annurev.pathmechdis.3.121806.154305.Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008; 3:157-88. doi: 10.1146/annurev.pathmechdis.3.121806.154305.Storz P. Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2017 May;14(5):296-304. doi: 10.1038/nrgastro.2017.12.Storz P. Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2017 May;14(5):296-304. doi: 10.1038/nrgastro.2017.12.Wang CC, Li K, Gaylord S. Wang et al. Respond. Am J Public Health. 2019 Sep;109(9): e5-e6. doi: 10.2105/AJPH.2019.305239.Wang CC, Li K, Gaylord S. Wang et al. Respond. Am J Public Health. 2019 Sep;109(9): e5-e6. doi: 10.2105/AJPH.2019.305239.Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature. 2008 Feb 21;451(7181):990-3. doi: 10.1038/nature06536.Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature. 2008 Feb 21;451(7181):990-3. doi: 10.1038/nature06536.Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology. 2019 May;156(7):2041-2055. doi: 10.1053/j.gastro.2018.12.039.Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology. 2019 May;156(7):2041-2055. doi: 10.1053/j.gastro.2018.12.039.Haigis KM. KRAS Alleles: The Devil Is in the Detail. Trends Cancer. 2017 Oct;3(10):686-697. doi: 10.1016/j.trecan.2017.08.006.Haigis KM. KRAS Alleles: The Devil Is in the Detail. Trends Cancer. 2017 Oct;3(10):686-697. doi: 10.1016/j.trecan.2017.08.006.Haigis KM. KRAS Alleles: The Devil Is in the Detail. Trends Cancer. 2017 Oct;3(10):686-697. doi: 10.1016/j.trecan.2017.08.006.Haigis KM. KRAS Alleles: The Devil Is in the Detail. Trends Cancer. 2017 Oct;3(10):686-697. doi: 10.1016/j.trecan.2017.08.006.Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003 Dec;4(6):437-50. doi: 10.1016/s1535-6108(03)00309-x.Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003 Dec;4(6):437-50. doi: 10.1016/s1535-6108(03)00309-x.Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. New England Journal of Medicine. 1995; 333:970-74.Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. New England Journal of Medicine. 1995; 333:970-74.Yonezawa A, Masuda S, Katsura T, Inui K. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol. 2008 Sep;295(3): C632-41. doi: 10.1152/ajpcell.00019.2008.Yonezawa A, Masuda S, Katsura T, Inui K. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol. 2008 Sep;295(3): C632-41. doi: 10.1152/ajpcell.00019.2008.Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005 May;7(5):469-83. doi: 10.1016/j.ccr.2005.04.023.Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005 May;7(5):469-83. doi: 10.1016/j.ccr.2005.04.023.Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006 May 15;20(10):1218-49. doi: 10.1101/gad.1415606.Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006 May 15;20(10):1218-49. doi: 10.1101/gad.1415606.Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006 Nov 15;20(22):3130-46. doi: 10.1101/gad.1478706.Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006 Nov 15;20(22):3130-46. doi: 10.1101/gad.1478706.Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. American Journal of Pathology. 2000; 156:1767-71.Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. American Journal of Pathology. 2000; 156:1767-71.Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324:217.Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324:217.Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genetics and Cytogenetics. 2005; 158:119-25.Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genetics and Cytogenetics. 2005; 158:119-25.Hofstatter EW, Domchek SM, Miron A, et al. PALB2 mutations in familial breast and pancreatic cancer. Familial Cancer. 2011; 10:225-31.Hofstatter EW, Domchek SM, Miron A, et al. PALB2 mutations in familial breast and pancreatic cancer. Familial Cancer. 2011; 10:225-31.Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011 Jun;10(2):225-31. doi: 10.1007/s10689-011-9426-1.Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011 Jun;10(2):225-31. doi: 10.1007/s10689-011-9426-1.Bakker JL, de Winter JP. A role for ATM in hereditary pancreatic cancer. Cancer Discov. 2012 Jan;2(1):14-5. doi: 10.1158/2159-8290.CD-11-0318.Bakker JL, de Winter JP. A role for ATM in hereditary pancreatic cancer. Cancer Discov. 2012 Jan;2(1):14-5. doi: 10.1158/2159-8290.CD-11-0318.

The authors declare that there are no conflicts of interest present.